SynBiotic (DB: SBX)

Currency in EUR

Last close As at 04/02/2023

EUR12.24

0.80 (6.99%)

Market capitalisation

EUR42m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer

SynBiotic — Management update – on track

Consumer

SynBiotic — Further acquisitions

Consumer

SynBiotic — Building a cannabis platform

Consumer

SynBiotic — Working together

Sector

Consumer

Equity Analyst

Sara Welford

Sara Welford

Director, Consumer

Key Management

  • Alexander Guercueyan

    CFO

  • Lars Müller

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 14.4 (21.0) (46.3)
Relative 3.8 (32.5) (46.0)
52 week high/low €23.4/€10.1

Financials

SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.

Research

Consumer

SynBiotic — Further acquisitions

Consumer

SynBiotic — Building a cannabis platform

Consumer

SynBiotic — Working together

Thematics

Consumer

ConsumerWatch – January 2023

Consumer

ConsumerWatch – October 2022

Consumer

IPO apocalypse

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free